Volume | 14,271,416 |
|
|||||
News | - | ||||||
Day High | 41.86 | Low High |
|||||
Day Low | 40.75 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Bristol Myers Squibb Co | BMY | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
41.38 | 40.75 | 41.86 | 41.20 | 41.48 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
93,519 | 14,271,416 | $ 41.43 | $ 591,275,454 | - | 39.91 - 66.38 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:59:49 | 10 | $ 41.27 | USD |
Bristol Myers Squibb (BMY) Options Flow Summary
Bristol Myers Squibb Co Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
83.31B | 2.02B | - | 45.01B | 8.03B | 3.97 | 10.38 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Bristol Myers Squibb News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BMY Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 40.85 | 43.19 | 40.75 | 42.13 | 13,242,854 | 0.42 | 1.03% |
1 Month | 44.34 | 44.34 | 39.91 | 41.69 | 14,831,893 | -3.07 | -6.92% |
3 Months | 51.65 | 54.475 | 39.91 | 45.47 | 13,645,577 | -10.38 | -20.10% |
6 Months | 52.62 | 55.035 | 39.91 | 48.77 | 15,592,247 | -11.35 | -21.57% |
1 Year | 64.96 | 66.38 | 39.91 | 52.45 | 13,663,565 | -23.69 | -36.47% |
3 Years | 67.32 | 81.435 | 39.91 | 62.54 | 11,742,339 | -26.05 | -38.70% |
5 Years | 47.33 | 81.435 | 39.91 | 60.79 | 12,337,680 | -6.06 | -12.80% |
Bristol Myers Squibb Description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power. |